The Potential of Camostat in COVID-19

Inclusion Criteria * Aged ≥18 * Willing to participate and fill out a daily symptom diary * Willing to take the parameters such as blood oxygenation and temperature * Willing to attend follow-up visits both by phone as at the clinic * Capable of understanding the commitment in the trial * Signed informed consent * Signs and symptoms suggestive of COVID disease in absence of hospitalization criteria as defined by the flowchart used at the emergency department of our institution (appendix 4), present for maximum 5 days and confirmed by PCR. * OR documented COVID-19 infection by PCR with CT value below the threshold of 30 in asymptomatic individuals. * For women of childbearing potential\*: they should be willing to use highly effective method of contraception during treatment and until the end of study defined as having a failure rate of less than 1% per year when used consistently and correctly. Such methods include: * combined (estrogen and progestogen containing) hormonal contraception * associated with inhibition of ovulation: oral, intravaginal or transdermal * progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable * intrauterine device (IUD) and intrauterine hormone-releasing system ( IUS) * bilateral tubal occlusion * vasectomised partner * sexual abstinence * For men of reproductive potential\*\*: condom should be used as contraception during treatment and until the end of study when having a partner of childbearing potential * a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. * a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy. Exclusion Criteria * Inability to make a decision to participate * Pregnant or breast feeding * Inability to take oral medication * Inability to provide informed written consent * Known hypersensitivity towards Camostat or other Serine protease inhibitors * Any condition that, in the Investigator's opinion, prevents adequate compliance with study therapy. * Any COVID infection at risk for hospitalisation as described in the emergency department flowchart (cfr appendix 4) * With regard to exclusion of women of child-bearing potential, women who tell us they know they are pregnant are excluded. All women of child-bearing potential who test positive for pregnancy by urine test at first visit are excluded. * Severe chronic pancreatitis requiring suction of gastric juice, fasting or abstention from drinking * Postoperative reflux oesophagitis due to reflux or gastric juice * Postoperative reflux oesophagitis (if improvement of symptoms is not observed).